๐๐๐บ๐ถ๐ป๐ฎ๐ฟ๐ ๐๐ฟ๐ผ๐๐ฝ, ๐๐น๐ผ๐ฏ๐ฎ๐น ๐๐ถ๐ณ๐ฒ ๐ฆ๐ฐ๐ถ๐ฒ๐ป๐ฐ๐ฒ๐ ๐๐ผ๐ป๐๐๐น๐๐ฎ๐ป๐ฐ๐ #artificialintelligence #realworlddata #mergersandacquisitions #realworldevidence #productlifecycle #regulatory #pharmacovigilence #bioprocessing #cdmo #clinicaltrials #consultancy #eclinical #saas #ecoa
About us
Luminary Group, headquartered at St Magnus House, 3 Lower Thames Street, Central London, EC3R 6HD, is an international executive search and business consultancy specializing in the Life Sciences and Pharmaceutical sectors. Our expertise lies within the Real World Evidence, eClinical, Artificial Intelligence, Consulting and Biotechnology disciplines with localized insights and specialized knowledge. Executive Search - Tailored executive search solutions to identify and recruit top talent for key leadership positions ranging from Chairman, Board, CEO, CCO, COO, CPO - AVP Design and Recruitment for Commercial Team Organization -Strategic planning and talent acquisition services to build high-performing commercial teams aligned with business goals. Design and Recruitment for Operations Team Organization -Expert guidance in structuring and staffing operations teams for efficient and effective business operations. Data Partnerships, Business Partnerships and M&A Consulting -Advisory assistance in forging data partnerships, leveraging our extensive network of leading RWE, RWD, and AI enterprises across the US and Europe. Additionally, we aid in cultivating business collaborations with biotechnology firms and guiding through mergers and acquisitions to foster growth and innovation. Operating globally with a presence in the USA, Europe, APAC, and the Middle East, we take pride in our exclusive talent pool, ranging from C-Suite to Managerial levels, and our exclusive partnerships with returning clients and candidates. Our collaborations extend across a diverse range of companies, from Corporate to innovative Start-Ups. For additional details, please explore our website: www.luminarygroup.co.uk
- Website
-
www.luminarygroup.co.uk
External link for Luminary Group
- Industry
- Business Consulting and Services
- Company size
- 11-50 employees
- Headquarters
- City of London
- Type
- Privately Held
- Founded
- 2023
- Specialties
- Executive Search, Headhunting, Consulting, Life Sciences, Pharmacovigilence, Regulatory Affairs, CMC, Biotechnology, Diagnostics, CRO, Clinical Trials, Cell & Gene Therapy, Machine Learning, Real World Evidence, Real World Data, eClinical, eCOA, RPO, FSP, Corporate Development, Partnerships, Data Partnerships, RWE, RWD, and Artificial Intelligence
Locations
-
Primary
City of London , GB
Employees at Luminary Group
Updates
-
๐๐จ ๐ฝ๐ฎ๐ป๐ฒ๐น ๐ณ๐ผ๐น๐น๐ผ๐๐ ๐๐๐โ๐ ๐น๐ฒ๐ฎ๐ฑ ๐ผ๐ป ๐ช๐ฒ๐ด๐ผ๐๐, ๐ฟ๐ฒ๐ฐ๐ผ๐บ๐บ๐ฒ๐ป๐ฑ๐ถ๐ป๐ด ๐๐๐ฒ ๐๐ผ ๐ฝ๐ฟ๐ฒ๐๐ฒ๐ป๐ ๐ฐ๐ฎ๐ฟ๐ฑ๐ถ๐ฎ๐ฐ ๐ฒ๐๐ฒ๐ป๐๐ European Renal Association (ERA) regulators are poised to approve Novo Nordisk blockbuster drug Buy Wegovy to reduce the risk of cardiovascular events in patients who are overweight or obese โฆ https://lnkd.in/d3ZirRAr
-
๐๐ฎ๐น๐น๐ถ๐ฑ๐ถ๐๐ฎ๐ ๐ฐ๐น๐ฎ๐ถ๐บ๐ ๐บ๐ถ๐ฑ-๐๐๐ฎ๐ด๐ฒ ๐๐ถ๐ป ๐ณ๐ผ๐ฟ ๐ฟ๐ฎ๐ฟ๐ฒ ๐น๐ถ๐๐ฒ๐ฟ ๐ฑ๐ถ๐๐ฒ๐ฎ๐๐ฒ ๐ฑ๐ฟ๐๐ด Calliditas Therapeutics NOX enzyme inhibitor succeeded in a Phase 2b trial in people with a rare liver disease that features inflammation and injury in the โฆRenee Aguiar-Lucander https://lnkd.in/dhYnTqdP
Calliditas claims mid-stage win for rare liver disease drug
https://endpts.com
-
๐๐๐๐ฟ๐ฎ๐ญ๐ฒ๐ป๐ฒ๐ฐ๐ฎ ๐ฑ๐ฒ๐๐ฎ๐ถ๐น๐ โ๐๐ฒ๐ฟ๐ ๐ฎ๐บ๐ฏ๐ถ๐๐ถ๐ผ๐๐โ ๐๐๐ฟ๐ฎ๐๐ฒ๐ด๐ ๐ณ๐ผ๐ฟ ๐ฒ๐ฎ๐ฟ๐น๐-๐๐๐ฎ๐ด๐ฒ ๐ผ๐ฏ๐ฒ๐๐ถ๐๐ ๐ฝ๐ฟ๐ผ๐ด๐ฟ๐ฎ๐บ๐ AstraZeneca plans to develop treatment options for people with different BMIs as part of its โvery ambitiousโ obesity strategy. AstraZeneca CEO Pascal Soriot on Thursday https://lnkd.in/dMHVp_ii
AstraZeneca details โvery ambitiousโ strategy for early-stage obesity programs
https://endpts.com
-
๐ฉ๐ถ๐ธ๐ถ๐ป๐ด ๐๐ผ ๐ฝ๐๐๐ต ๐ผ๐ฏ๐ฒ๐๐ถ๐๐ ๐ฑ๐ฟ๐๐ด ๐๐ผ ๐ฃ๐ต๐ฎ๐๐ฒ ๐ฏ ๐ถ๐ป ๐ฏ๐ถ๐ฑ ๐๐ผ ๐ฟ๐ฒ๐ฎ๐ฐ๐ต ๐บ๐ฎ๐ฟ๐ธ๐ฒ๐ ๐ณ๐ฎ๐๐๐ฒ๐ฟ Viking Therapeutics, Inc.is stepping on the gas with its experimental GLP-1/GIP receptor agonist for obesity, forgoing a Phase 2b study and jumping right into Phase โฆBrian Lian https://lnkd.in/drHmcdQG
Viking to push obesity drug to Phase 3 in bid to reach market faster
https://endpts.com
-
๐ฆ๐ฎ๐ป๐ผ๐ณ๐ถ ๐ฒ๐๐ฒ๐ ๐ฅ๐ฆ๐ฉ ๐ฎ๐ป๐๐ถ๐ฏ๐ผ๐ฑ๐ ๐ณ๐ผ๐ฟ ๐ถ๐๐ ๐ป๐ฒ๐ ๐ ๐ฏ๐น๐ผ๐ฐ๐ธ๐ฏ๐๐๐๐ฒ๐ฟ ๐ฑ๐ฟ๐๐ด ๐๐ต๐ถ๐น๐ฒ ๐๐๐ฝ๐ถ๐ ๐ฒ๐ป๐ ๐ฏ๐ฟ๐ถ๐ป๐ด๐ ๐ถ๐ป ๐ฟ๐ฒ๐ฐ๐ผ๐ฟ๐ฑ ๐๐ฎ๐น๐ฒ๐ Sanofi's RSV antibody Beyfortusยฎ (nirsevimab-alip) is still on track to reach blockbuster status this year as the company expands manufacturing capacityโฆ https://lnkd.in/dgibKKpc
Sanofi eyes RSV antibody for its next blockbuster drug while Dupixent brings in record sales
https://endpts.com
-
We are thrilled to announce the launch of our brand new website: www.luminarygroup.co.uk Luminary Group, is an international executive search and business consultancy specializing in the Life Sciences and Pharmaceutical sectors. Contact us today! #NewWebsite #LuminaryGroup #DigitalLaunch #ExploreNow
-
๐๐ฝ๐๐ฒ๐ป ๐ฝ๐ฎ๐๐ ๐๐ฎ๐ ๐ข๐ป๐ฒ $๐ญ๐ญ๐ญ๐ ๐๐ฝ๐ณ๐ฟ๐ผ๐ป๐ ๐ณ๐ผ๐ฟ ๐ฒ๐ -๐จ๐ฆ ๐ฟ๐ถ๐ด๐ต๐๐ ๐๐ผ ๐ฝ๐ฒ๐ฑ๐ถ๐ฎ๐๐ฟ๐ถ๐ฐ ๐ฏ๐ฟ๐ฎ๐ถ๐ป ๐๐๐บ๐ผ๐ฟ ๐ฑ๐ฟ๐๐ด In another move to boost its oncology portfolio, Ipsen is handing Day One Biopharmaceuticals $111 million upfront so it can take the pediatric brain tumor โฆDavid Loew , Ipsen https://lnkd.in/dw-zccPr
Ipsen pays Day One $111M upfront for ex-US rights to pediatric brain tumor drug
https://endpts.com
-
๐ก๐ผ๐๐ฎ๐ฟ๐๐ถ๐ ๐ฝ๐ฎ๐๐ $๐ญ๐ฑ๐ฌ๐ ๐๐ฝ๐ณ๐ฟ๐ผ๐ป๐, ๐ถ๐ป๐ฐ๐น๐๐ฑ๐ถ๐ป๐ด $๐ฎ๐ฑ๐ ๐ถ๐ป ๐ฒ๐พ๐๐ถ๐๐, ๐ณ๐ผ๐ฟ ๐๐ฟ๐ฒ๐ป ๐๐ถ๐ผโ๐ ๐ฏ๐ถ๐๐ฝ๐ฒ๐ฐ๐ถ๐ณ๐ถ๐ฐ๐ Dren Bio, Inc. inked a research pact with Novartis for select myeloid engagers to treat cancer, marking its second collaboration with a large pharma. The Swiss โฆNenad Tomasevic https://lnkd.in/d_vJXxEN
Novartis pays $150M upfront, including $25M in equity, for Dren Bioโs bispecifics
https://endpts.com
-
๐ฃ๐ณ๐ถ๐๐ฒ๐ฟ ๐๐ฎ๐๐ ๐ต๐ฒ๐บ๐ผ๐ฝ๐ต๐ถ๐น๐ถ๐ฎ ๐ ๐ด๐ฒ๐ป๐ฒ ๐๐ต๐ฒ๐ฟ๐ฎ๐ฝ๐ ๐ฟ๐ฒ๐ฑ๐๐ฐ๐ฒ๐ฑ ๐ฏ๐น๐ฒ๐ฒ๐ฑ๐ถ๐ป๐ด ๐ถ๐ป ๐ฃ๐ต๐ฎ๐๐ฒ ๐ฏ ๐๐๐๐ฑ๐ Pfizer announced on Wednesday morning that its gene therapy for hemophilia A met its primary objective in a key clinical trial, and the company plans โฆ https://lnkd.in/dfWGG4hR
Pfizer says hemophilia A gene therapy reduced bleeding in Phase 3 study
https://endpts.com